// Unabhängig · Evidenzbasiert · Keine Affiliate-Vergütung Bewertungsmatrix Offenlegung

Übersetzung in Bearbeitung. Der englische Originaltext wird unten angezeigt; die lokalisierte Terminologie wird vor der Freigabe von einer muttersprachlichen klinischen Redaktion geprüft.

// coaching · clinical report

Noom Clinical Report (2026): Behavior-Change Program with Tracker Attached

Score Breakdown

Klinische Bewertungsmatrix — 100 Punkte
Kriterium Gewichtung Teilnote
Evidenz & Validierung 25% 76/100
Klinische Genauigkeit 20% 62/100
KI-Erkennungsleistung 15% 50/100
Makronährstoff- & Zielrahmen 10% 60/100
Verhaltenshaftung 10% 68/100
Datenschutz & Sicherheit 10% 64/100
Kosten & Zugänglichkeit 10% 50/100
Gesamt 100% 62/100

Stärken / Einschränkungen

Stärken

  • Psychology curriculum is genuinely thoughtful
  • Color-coded food categorization is beginner-intuitive
  • Optional human coaching as part of the program
  • Multiple published observational studies on weight outcomes

Einschränkungen

  • ~$209/year — most expensive in the category by far
  • Trial-conversion pricing is aggressive
  • Calorie tracker functionality is mid-tier at best
  • Cancellation friction is higher than competitors
  • Dropout-attrition handling in published studies has drawn independent criticism

Architecture and Position

Noom delivers a structured behavior-change program (psychology curriculum + coaching + food categorization) rather than a primary calorie tracker. The published evidence base is the strongest of any app on this list — multiple observational studies on weight outcomes from program users. The criticism that recurs in independent reviews concerns attrition handling: published outcomes are conditioned on program completion, which selects for users who were already engaged.

Clinical Evaluation Framework Scoring

CriterionWeightSub-score
Evidence & Validation25%76/100
Clinical Accuracy20%62/100
AI Recognition Performance15%50/100
Macronutrient & Goal Framework10%60/100
Behavioral Adherence10%68/100
Privacy & Security10%64/100
Cost & Accessibility10%50/100

Overall: 62/100. Evidence Grade B.


Last reviewed: 2026-05-22. See our Clinical Evaluation Framework and no-affiliate disclosure.